Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) to a moderate buy rating in a research report report published on Thursday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Leerink Partners initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 price target for the company. Evercore initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, December 29th. Guggenheim restated a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.40.

Damora Therapeutics, Inc. Common Stock Stock Performance

Damora Therapeutics, Inc. Common Stock stock opened at $24.75 on Thursday. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The firm has a 50 day moving average price of $27.04 and a 200 day moving average price of $22.79. The company has a market capitalization of $1.49 billion, a PE ratio of -2.05 and a beta of 1.59.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently modified their holdings of DMRA. Two Sigma Investments LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $76,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $49,000. Connective Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $100,000. Sigma Planning Corp purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $334,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $266,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.